Journal Article

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy

Luo, Lianxiang, Yang, Mingrong, Leung, Elaine Lai-Han, Wang, Wenjun, Yao, Xiaojun, Wei, Hong, Liu, Haizhou, Zhang, Yizhong, Khan, Imran, Shi, Axi, Fan, Xingxing, Liu, Di, Xie, Yajia, Li, Jian, Lu, Jingguang, Liao, Junyi, Huang, Jumin, Wu, Jianlin, Liu, Liang, Fu, Yu, Xie, Ying, Jiang, Zhihong, Jiang, Zebo, Yan, Peiyu, Li, Runze, Cai, Jun, Cao, Yabing, Hsiao, WL Wendy, Wu, Qibiao, Wang, Lin, Yuan, Jing, Lai, Huanling, Wang, Yuwei, Liu, Zhongqiu

2022

Overview

ObjectiveProgrammed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut microbiota plays a crucial role in immunotherapy sensitisation and Panax ginseng has been shown to possess immunomodulatory potential. In this study, we aimed to investigate whether the combination treatment of ginseng polysaccharides (GPs) and αPD-1 monoclonal antibody (mAb) could sensitise the response by modulating gut microbiota.DesignSyngeneic mouse models were administered GPs and αPD-1 mAb, the sensitising antitumour effects of the combination therapy on gut microbiota were assessed by faecal microbiota transplantation (FMT) and 16S PacBio single-molecule real-time (SMRT) sequencing. To assess the immune-related metabolites, metabolomics analysis of the plasma samples was performed.ResultsWe found GPs increased the antitumour response to αPD-1 mAb by increasing the microbial metabolites valeric acid and decreasing L-kynurenine, as well as the ratio of Kyn/Trp, which contributed to the suppression of regulatory T cells and induction of Teff cells after combination treatment. Besides, the microbial analysis indicated that the abundance of Parabacteroides distasonis and Bacteroides vulgatus was higher in responders to anti-PD-1 blockade than non-responders in the clinic. Furthermore, the combination therapy sensitised the response to PD-1 inhibitor in the mice receiving microbes by FMT from six non-responders by reshaping the gut microbiota from non-responders towards that of responders.ConclusionOur results demonstrate that GPs combined with αPD-1 mAb may be a new strategy to sensitise non-small cell lung cancer patients to anti-PD-1 immunotherapy. The gut microbiota can be used as a novel biomarker to predict the response to anti-PD-1 immunotherapy.

• Publisher: BMJ Publishing Group Ltd and British Society of Gastroenterology,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Animal models / Animals / Antibodies, Monoclonal - pharmacology / Apoptosis / B7-H1 Antigen - metabolism / Biomarkers / cancer / cancer immunobiology / Cancer therapies / Carcinoma, Non-Small-Cell Lung - therapy / Cell Death / Cloning / drug resistance / Fatty acids / Flow cytometry / Gastrointestinal Microbiome - physiology / Ginseng / Gut Microbiota / Humans / Immunologic Factors - pharmacology / Immunomodulation / Immunoregulation / Immunotherapy / Immunotherapy - methods / Intestinal microflora / Kynurenine - pharmacology / Laboratories / Ligands / Lung cancer / Lung Neoplasms - therapy / Lymphocytes T / Medical research / Metabolomics / Mice / Microbiota / Monoclonal antibodies / Non-small cell lung carcinoma / Panax - metabolism / Panax ginseng / PD-1 protein / PD-L1 protein / Polysaccharides / Polysaccharides - pharmacology / prebiotic / probiotics / Response rates / Small cell lung carcinoma / Transplantation / Tryptophan / Tryptophan - pharmacology / Tumor necrosis factor-TNF / Valeric acid / Variance analysis